SPDR S&P Biotech ETF (XBI) Stock Price, News, Quotes-Moomoo

US ETFDetailed Quotes

XBI SPDR S&P Biotech ETF

Watchlist

90.060
+0.170+0.19%

Close Dec 31 16:00 ET

91.070High89.370Low

Intraday

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Top U.S. Health Care Mid-cap Stocks and Their Quant Ratings
Seeking AlphaDec 31, 2024 10:46 ET
Dogs Of The Dow: Top 10 High-Yield Stocks Offering Dividends Up To 6.8% In 2025
BenzingaDec 31, 2024 10:45 ET
Why Did Pfizer's Exit From the Gene Therapy Program Hit Sangamo Hard?
Seeking AlphaDec 31, 2024 09:55 ET
Trim the Mag 7 and Invest in Lower Valuation Dividend Growth Stocks – Miramar Capital
Seeking AlphaDec 30, 2024 14:42 ET
Market Falling Monday, With Few Santa Clause 'Rally' Days Left | Live Stock
Kevin TraversDec 30, 2024 11:01 ET
Here Are Morgan Stanley's Key Oncology Catalysts for 2025
Seeking AlphaDec 28, 2024 10:31 ET

Comments

topcing

Nov 4, 2024 21:29

$SPDR S&P Biotech ETF (XBI.US)$ yea

股勇者

Oct 25, 2024 10:17

$SPDR S&P Biotech ETF (XBI.US)$ 100 month end? ok?

Bellaah

Sep 11, 2024 11:10

$SPDR S&P Biotech ETF (XBI.US)$ 95

Moomoo Learn

Sep 6, 2024 03:05

Columns Navigating the wave of lower interest rates

Given the strong market expectations for a Federal Reserve rate cut, as indicated by the CME data with a 57% chance for a 25-basis-point reduction and a 43% chance for a 50-basis-point cut in September, investors are poised to reconsider their strategies.
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...

CPI hits 3-year low: How will it sway the Fed rate decision?

frankinglily

Aug 25, 2024 22:03

Argument:
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...

Powell said it's time to cut: Will the market go wild?